Health ❯ Healthcare ❯ Clinical Trials

Phase III Trials

Efficacy Studies MATTERHORN Trial TULIP-SC Trial DESTINY-Breast05 Trial KOMET Trial TROPION-Breast02 Patient Outcomes Daraxonrasib Giredestrant Trials ASPEN Trial

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

Approval by October 9, 2026 would establish the first immunotherapy-based adjuvant option for patients with dMMR/MSI-H stage III colon cancer.

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

EMERALD-3 Trial Shows Progression-Free Survival Win for STRIDE Plus Lenvatinib With TACE

FDA Approves Xocova as First U.S. Post-Exposure COVID-19 Antiviral

FDA Approves Durvalumab Plus BCG for High‑Risk Non‑Muscle Invasive Bladder Cancer

FDA Approves Datroway as First‑Line Option for Immunotherapy‑Ineligible Triple‑Negative Breast Cancer

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

Moderna Begins Phase III Trial of mRNA Bird Flu Vaccine in UK and US

Roche Files MS Drug Fenebrutinib With Regulators Despite Trial Deaths

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

FDA Clears Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes